Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.43 |
| ▸ | DHODH | Q02127 | 4/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108390 | 0.88 | METTL3 (0.44) | METTL3PTGER1DHODHMCL1CTSV | |
| SCHEMBL12108401 | 0.86 | METTL3 (0.42) | METTL3DHODHCTSVCTSL | |
| SCHEMBL12108387 | 0.86 | METTL3 (0.46) | METTL3DHODHMCL1TSHRHIF1A | |
| SCHEMBL12108361 | 0.82 | METTL3 (0.46) | METTL3DHODHTSHR | |
| SCHEMBL12108366 | 0.82 | METTL3 (0.59) | METTL3 | |
| SCHEMBL12108370 | 0.81 | METTL3 (0.44) | METTL3DHODHTSHR | |
| SCHEMBL12108378 | 0.81 | METTL3 (0.43) | METTL3DHODHTSHRHIF1A | |
| SCHEMBL1300646 | 0.80 | METTL3 (0.44) | METTL3TSHRHIF1A | |
| SCHEMBL12108382 | 0.80 | METTL3 (0.41) | METTL3DHODHTSHR | |
| SCHEMBL12110682 | 0.80 | PIK3CA (0.42) | METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2009089263-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PTGER1 3479/4885DHODH 783/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PTGER1 3479/4885DHODH 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.